Among the current targeted therapies, non-small-cell lung cancer targets include EGFR (epidermal growth factor receptor), EML4-ALK fusion gene (43), ROS1 fusion gene, RAS mutation, and C-MET amplification. Here, EGFR is linked to non-small cell lung carcinoma.